Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts. more
Time Frame | LYRA | Sector | S&P500 |
---|---|---|---|
1-Week Return | -12.53% | 0.31% | -1.26% |
1-Month Return | 1.94% | 0.6% | -4.16% |
3-Month Return | -14.97% | -9.44% | -0.46% |
6-Month Return | -37.97% | -5.15% | 3.58% |
1-Year Return | -96.4% | 0.33% | 22.47% |
3-Year Return | -95.21% | 4.53% | 25.13% |
5-Year Return | -98.98% | 35.98% | 77.7% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | 285.00K | 1.36M | 1.56M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":18.29,"profit":true},{"date":"2022-12-31","value":87.48,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 27.00K | 95.00K | 1.00M | 1.07M | 48.03M | [{"date":"2019-12-31","value":0.06,"profit":true},{"date":"2020-12-31","value":0.2,"profit":true},{"date":"2021-12-31","value":2.08,"profit":true},{"date":"2022-12-31","value":2.22,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | (27.00K) | (95.00K) | 285.00K | 296.00K | 1.56M | [{"date":"2019-12-31","value":-1.73,"profit":false},{"date":"2020-12-31","value":-6.1,"profit":false},{"date":"2021-12-31","value":18.29,"profit":true},{"date":"2022-12-31","value":19,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | (Infinity%) | (Infinity%) | 100.00% | 21.72% | 100.00% | [{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":21.72,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Expenses | 16.52M | 22.21M | 43.90M | 56.35M | 68.68M | [{"date":"2019-12-31","value":24.05,"profit":true},{"date":"2020-12-31","value":32.34,"profit":true},{"date":"2021-12-31","value":63.92,"profit":true},{"date":"2022-12-31","value":82.05,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (16.52M) | (22.21M) | (43.62M) | (56.31M) | (67.12M) | [{"date":"2019-12-31","value":-1651900000,"profit":false},{"date":"2020-12-31","value":-2220900000,"profit":false},{"date":"2021-12-31","value":-4361500000,"profit":false},{"date":"2022-12-31","value":-5630600000,"profit":false},{"date":"2023-12-31","value":-6712000000,"profit":false}] |
Total Non-Operating Income/Expense | 426.00K | 164.00K | 204.00K | 2.08M | 8.59M | [{"date":"2019-12-31","value":4.96,"profit":true},{"date":"2020-12-31","value":1.91,"profit":true},{"date":"2021-12-31","value":2.37,"profit":true},{"date":"2022-12-31","value":24.23,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (16.31M) | (22.13M) | (43.51M) | (55.27M) | (62.62M) | [{"date":"2019-12-31","value":-1630600000,"profit":false},{"date":"2020-12-31","value":-2212700000,"profit":false},{"date":"2021-12-31","value":-4351300000,"profit":false},{"date":"2022-12-31","value":-5526500000,"profit":false},{"date":"2023-12-31","value":-6262100000,"profit":false}] |
Income Taxes | (213.00K) | (82.00K) | (1.10M) | 13.00K | 59.00K | [{"date":"2019-12-31","value":-361.02,"profit":false},{"date":"2020-12-31","value":-138.98,"profit":false},{"date":"2021-12-31","value":-1869.49,"profit":false},{"date":"2022-12-31","value":22.03,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | (16.09M) | (22.05M) | (42.41M) | (55.28M) | (62.68M) | [{"date":"2019-12-31","value":-1609300000,"profit":false},{"date":"2020-12-31","value":-2204500000,"profit":false},{"date":"2021-12-31","value":-4241000000,"profit":false},{"date":"2022-12-31","value":-5527800000,"profit":false},{"date":"2023-12-31","value":-6268000000,"profit":false}] |
Income From Continuous Operations | (16.31M) | (22.13M) | (43.51M) | (55.28M) | (61.76M) | [{"date":"2019-12-31","value":-1630600000,"profit":false},{"date":"2020-12-31","value":-2212700000,"profit":false},{"date":"2021-12-31","value":-4351300000,"profit":false},{"date":"2022-12-31","value":-5527800000,"profit":false},{"date":"2023-12-31","value":-6175900000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (16.09M) | (22.05M) | (42.41M) | (55.28M) | (62.68M) | [{"date":"2019-12-31","value":-1609300000,"profit":false},{"date":"2020-12-31","value":-2204500000,"profit":false},{"date":"2021-12-31","value":-4241000000,"profit":false},{"date":"2022-12-31","value":-5527800000,"profit":false},{"date":"2023-12-31","value":-6268000000,"profit":false}] |
EPS (Diluted) | (1.32) | (20.21) | (3.35) | (1.75) | (1.25) | [{"date":"2019-12-31","value":-132,"profit":false},{"date":"2020-12-31","value":-2021,"profit":false},{"date":"2021-12-31","value":-335,"profit":false},{"date":"2022-12-31","value":-175,"profit":false},{"date":"2023-12-31","value":-125,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
LYRA | |
---|---|
Cash Ratio | 3.45 |
Current Ratio | 3.64 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
LYRA | |
---|---|
ROA (LTM) | -42.29% |
ROE (LTM) | -186.18% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
LYRA | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.74 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.26 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
LYRA | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 8.70 |
P/B | 0.62 |
Price/FCF | NM |
EV/R | 153.77 |
EV/Ebitda | 0.66 |
Lyra Therapeutics Inc (LYRA) share price today is $0.1892
Yes, Indians can buy shares of Lyra Therapeutics Inc (LYRA) on Vested. To buy Lyra Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in LYRA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Lyra Therapeutics Inc (LYRA) via the Vested app. You can start investing in Lyra Therapeutics Inc (LYRA) with a minimum investment of $1.
You can invest in shares of Lyra Therapeutics Inc (LYRA) via Vested in three simple steps:
The 52-week high price of Lyra Therapeutics Inc (LYRA) is $6.79. The 52-week low price of Lyra Therapeutics Inc (LYRA) is $0.16.
The price-to-earnings (P/E) ratio of Lyra Therapeutics Inc (LYRA) is
The price-to-book (P/B) ratio of Lyra Therapeutics Inc (LYRA) is 0.62
The dividend yield of Lyra Therapeutics Inc (LYRA) is 0.00%
The market capitalization of Lyra Therapeutics Inc (LYRA) is $12.38M
The stock symbol (or ticker) of Lyra Therapeutics Inc is LYRA